Becker's Healthcare August 26, 2024
Employers and employees spent more than $400 billion on obesity care in 2023; Novo Nordisk’s CEO said weight loss drug Wegovy can reduce these costs — an inverse of critics’ expectations.
For months, U.S. lawmakers have slammed Novo Nordisk’s monthly list prices of Ozempic ($969) and Wegovy ($1,349) because the drugs can be 10 to 15 times cheaper in other countries. The Denmark-based company has previously said the reason for these price disparities is because of America’s complex pharmaceutical industry.
“Unfortunately, even when we lower our prices, patients in the United States often don’t receive the savings — this is a problem,” a spokesperson told Becker’s in July. The company has said it receives about 60% of U.S....
Today's Sponsors
Today's Sponsor